Akebia stock plummets 28% after Auryxia exclusivity loss

Akebia Therapeutics saw its stock drop by 28% today. This decline comes after the company announced a public offering of common stock and shared some negative news about its financial situation. Last week, Akebia reported its earnings for the fourth quarter, which raised concerns among investors. The company's recent struggles include the loss of exclusivity for Auryxia, a treatment they offer. This has added to worries about its future profitability. The article emphasizes that this is not an investment recommendation. It encourages readers to do their own research before making financial decisions. Investing in stocks can be risky and volatile.